Insider · CIK 0001993078
Erin Catherine Carter
Files at GCTK (Glucotrack, Inc.). First filing -, latest -.
Erin Catherine Carter files SEC Form 4 as director at GCTK (Glucotrack, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Erin Catherine Carter has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 25, 2025 | GCTK Glucotrack, Inc. | AGrant or award Common Stock, par value $0.001 per share | +32 | $0.00 | $0 | 762 | Oct 7, 2025 |
| Jul 11, 2025 | GCTK Glucotrack, Inc. | AGrant or award Common Stock, par value $0.001 per share | +1,000 | $0.00 | $0 | 1,762 | Oct 7, 2025 |
| Oct 3, 2025 | GCTK Glucotrack, Inc. | AGrant or award Common Stock, par value $0.001 per share | +386 | $0.00 | $0 | 2,148 | Oct 7, 2025 |
| Oct 3, 2025 | GCTK Glucotrack, Inc. | AGrant or award Stock option (right to buy)derivative | +4,055 | $0.00 | $0 | 4,055 | Oct 7, 2025 |
| Dec 31, 2023 | GCTK Glucotrack, Inc. | AGrant or award Common Stock, par value $0.001 per share | +903 | $0.00 | $0 | 903 | Mar 31, 2025 |
| Apr 8, 2024 | GCTK Glucotrack, Inc. | AGrant or award Common Stock, par value $0.001 per share | +458 | $0.00 | $0 | 1,361 | Mar 31, 2025 |
| Nov 14, 2024 | GCTK Glucotrack, Inc. | CConversion Common Stock, par value $0.001 per share | +2,078 | $31.20 | $65k | 3,439 | Mar 31, 2025 |
| Mar 12, 2025 | GCTK Glucotrack, Inc. | XIn-the-money exercise Common Stock, par value $0.001 per share | +40,297 | $0.00 | $0 | 43,736 | Mar 31, 2025 |
| Mar 26, 2025 | GCTK Glucotrack, Inc. | AGrant or award Common Stock, par value $0.001 per share | +1,896 | $0.00 | $0 | 45,632 | Mar 31, 2025 |
| Jul 18, 2024 | GCTK Glucotrack, Inc. | POpen-market purchase Convertible Promissory Notederivative | - | $50,000.00 | - | - | Mar 31, 2025 |
| Nov 14, 2024 | GCTK Glucotrack, Inc. | CConversion Convertible Promissory Notederivative | - | $64,831.00 | - | 0 | Mar 31, 2025 |
| Nov 14, 2024 | GCTK Glucotrack, Inc. | AGrant or award Series A Common Warrantderivative | +2,078 | - | - | 2,078 | Mar 31, 2025 |
| Nov 14, 2024 | GCTK Glucotrack, Inc. | AGrant or award Series B Common Warrantderivative | +2,078 | - | - | 2,078 | Mar 31, 2025 |
| Mar 12, 2025 | GCTK Glucotrack, Inc. | XIn-the-money exercise Series B Common Warrantderivative | -2,078 | $0.00 | $0 | 0 | Mar 31, 2025 |
Questions about Erin Catherine Carter
Answered from the filings on this page, as of the latest one.
Is Erin Catherine Carter buying or selling?
Erin Catherine Carter has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Erin Catherine Carter's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Erin Catherine Carter has 0.
Where does Erin Catherine Carter file Form 4?
Erin Catherine Carter has filed Form 4 at GCTK (Glucotrack, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.